CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure Nature Metabolism Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3 eBioMedicine PDF] Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial. Semantic Scholar Cagrilintide, an amylin analogue, is a promising medication for weight loss by enhancing satiety, delaying gastric emptying, and suppressing appetite. In my patients, I have also seen increased CagriSema vs Tirzepatide: 23% Weight Loss in Phase 3 Trial